VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is expanding its use of human-relevant testing methods across its oncology research programs, aiming to generate more clinically informative preclinical data while reducing the number of animals required for drug development. The Switzerland-based company, with a key financial and regulatory presence in the U.S., outlined its implementation of New Approach Methodologies (NAMs) in an October 7, 2026, announcement.
NAMs are a collection of non-animal research techniques that include cell-based assays, computational modeling and other human-relevant systems. VERAXA is implementing these FDA-aligned methodologies across its preclinical research programs to improve the relevance of experimental findings to human biology while reducing animal testing. The strategy supports development of the company’s BiTAC® T-cell engagers, BiTAC-based antibody-drug conjugates and bispecific antibody-drug conjugates for the treatment of cancer.
New three-dimensional spheroid data reportedly reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates. In an ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, the company required about 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies. VERAXA says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity.
The move matters because it could accelerate the translation of preclinical findings into clinical trials while addressing growing regulatory and ethical pressure to reduce animal use. By adopting NAMs, VERAXA aims to generate data that better predict human responses, potentially increasing the probability of success for its antibody-based cancer pipeline. The strategy also aligns with the FDA’s push to modernize drug development through human-relevant testing approaches.
For investors, the announcement signals VERAXA’s commitment to efficient, human-relevant research that may reduce development costs and timelines. The company’s focus on BiTAC T-cell engagers and antibody-drug conjugates places it in the competitive oncology space, where predictive preclinical models are critical. As VERAXA continues to advance its pipeline, the integration of NAMs could differentiate its approach and support partnerships or regulatory submissions.
The full announcement was originally released by NEWMEDIAWIRE. More details on VERAXA Biotech (NASDAQ: VRXA) are available through IBN’s client partner page, and the latest news and updates relating to VRXA can be found in the company’s newsroom at https://ibn.fm/VRXA.
